Clever Culture Systems (ASX:CC5) has won an order from CSL Behring, which will lease the company’s innovative Automated Plate ...

The week’s insights come from equity strategist Lochlan Halloway’s latest analysis of CSL Ltd (ASX.CSL). CSL faces headwinds but shares remain cheap ahead of expected margin r ...

ASX healthcare has staged a comeback this week as CSL and Cochlear rebound and upcoming catalysts for several companies provide a lift.

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key ...

UBS says the worst is over for CSL, and has a bullish share price target for the global blood products company.

The market clawed back from a 1.6% tumble, but weakness in resources kept the ASX in the red as investors ... Read More The ...

Three dosing levels of enpatoran each reduced disease activity among patients with skin manifestations of cutaneous or ...

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower ...

Clever Culture Systems (ASX: CC5) has received an order from CSL Behring for the lease of an APAS® Independence instrument ...